Abstract, Snapshot, Market Analysis & Market Definition: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig's disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig's disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.The classification of Amyotrophic Lateral Sclerosis (ALS) Treatment includes Riluzole, Edaravone (Radicava) and Other and the proportion of Edaravone (Radicava) in 2017 is about 67.7%, Radicava is approved in Japan and Korea in 2015, and through the FDA in 2017. In 2018, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was 240 million US$ and it is expected to reach 380 million US$ by the end of 2025, with a CAGR of 6.9% during 2019-2025. This report focuses on the global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in United States, Europe and China
Market Segmentation: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Segmentation by Product Type : Breakdown of data from year 2014 to 2019 and forecast until 2025:
Riluzole
Edaravone (Radicava)
Other
Segmentation by Application : Breakdown of data from year 2014 to 2019 and forecast until 2025:
Hospital
Drugs Store
Other
Top Companies & Key Players: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
The report offers a detailed analysis of several leading Amyotrophic Lateral Sclerosis (ALS) Treatment manufacturers including:
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Key Insights Covered: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
Research Methodology: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other